{
  "docId": "019de073-3800-772b-871e-98f0ed79adc7",
  "docSlug": "3d30d84bb133b7b226440021781a4f91",
  "documentTitle": "23andMe | Investor Presentation Deck | 58 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 44,
  "pageCount": 58,
  "prevPage": 43,
  "nextPage": 45,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide outlines a standard clinical trial structure with patient inclusion criteria, study arms (Part A/B), and primary/secondary endpoints.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-3800-772b-871e-98f0ed79adc7/44",
  "deckHref": "/decks/019de073-3800-772b-871e-98f0ed79adc7",
  "deckJsonHref": "/decks/019de073-3800-772b-871e-98f0ed79adc7.json",
  "deckAnchorHref": "/decks/019de073-3800-772b-871e-98f0ed79adc7#slide-44",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.27
      },
      "kind": "diagram",
      "text": "Study Design: Phase 1, Openlabel, Non-Randomized, Multi-center",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2bd0d1c-f72c-481c-ad71-daf2529ae6f9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Abbreviations: AEs: Adverse Events; DLT: Dose limiting toxicity; DOR: duration of response; IV: intravenous; ORR: Objective Response Rate; OS: Overall Survival; PFS: Progression Free Survival; Q3W: every three weeks; RECIST: Response Evaluation Criteria in Solid Tumors; RP2D: Recommended Phase 2 Dose",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68538cd7-fd5a-4fac-89c6-672222a44666",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.53,
        "y": 0.38
      },
      "kind": "list",
      "text": "Primary: Part A: Safety (DLTs, AEs); Part B: Efficacy (ORR)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15699fa0-cfeb-4d40-b026-249198b44084",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.53,
        "y": 0.6
      },
      "kind": "list",
      "text": "Secondary and Exploratory: Efficacy (ORR [RECIST and iRECIST]), DoR, PFS, OS and Safety; Pharmacokinetics; Pharmacodynamic biomarkers",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e7f184d1-ad55-4fec-943b-f87c87ff2a6a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 1 Study of 23ME'610 in Patients with Locally Advanced or Metastatic Solid Malignancies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79ec077d-6872-4805-af3e-85074e1e0f46",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "110d7619-8cb6-459a-ba47-6eb0ee485fde",
      "evidence": "list/bullet: Secondary and Exploratory: Efficacy (ORR [RECIST and iRECIST]), DoR, PFS, OS and Safety; Pharmacokinetics; Pharmacodynamic biomarkers",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "2ec06551-7d03-4c95-93aa-be3f8f6db314",
      "evidence": "Standardized structure for Phase 1 oncology trials",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}